Hospital Clínico Universitario de Valencia
Hospital Clínico Universitario de Valencia
Valencia, Spain26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05708235 | |
| Hyperangulated vs Macintosh Blades for Intubation With Videolaryngoscopy in ICU | acute respiratory failure | Recruiting | Not applicable | 2026-09-21 | NCT06322719 | |
| Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 2 | 2026-09-11 | NCT05306041 | |
| Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis | Brain Metastases, Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-09-09 | NCT06315010 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma | gastroesophageal adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-18 | NCT07763171 | |
| Using Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-08-11 | NCT07268391 | |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-08-06 | NCT05232916 | |
| Is Hypoxemia Driving Outcome in Acute Hypoxemic Respiratory Failure? (HOMELAND Study) | Acute Hypoxemic Respiratory Failure, Respiration Disorders, respiratory failure, respiratory system disorder | Active, not recruiting | Not stated | 2026-07-17 | NCT07708506 | |
| EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia. | fibromyalgia, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, rheumatic disorder | Recruiting | Not applicable | 2026-07-15 | NCT07583056 | |
| Inhaled Sedation in Critically Ill Patients | Confusion, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cognitive disorder, delirium, nervous system disorder, psychiatric disorder | Recruiting | Phase 4 | 2026-06-29 | NCT07000526 | |
| NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | Newly Diagnosed Multiple Myeloma | Recruiting | Phase 3 | 2026-06-25 | NCT05558319 | |
| Study of Lacutamab in Peripheral T-cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-06-04 | NCT04984837 | |
| Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Phase 3 | 2026-05-15 | NCT05952206 | |
| Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 3 | 2026-05-01 | NCT01558921 | |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-29 | NCT06172127 | |
| Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm, rectum adenocarcinoma | Recruiting | Phase 2 | 2026-02-17 | NCT07407465 | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-12 | NCT02947685 | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-09-08 | NCT05063786 | |
| Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study) | cardiovascular disorder, hypertensive disorder, lung disorder, pulmonary hypertension, respiratory system disorder, vascular disorder | Recruiting | Not applicable | 2025-08-01 | NCT06495970 | |
| Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica" | Embolism and Thrombosis, Thromboembolism, cancer, cardiovascular disorder, neoplasm, vascular disorder | Recruiting | Not stated | 2025-05-16 | NCT03855592 | |
| Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies | Invasive Breast Cancer Early Stages | Recruiting | Not stated | 2025-05-14 | NCT03390894 | |
| Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2025-01-27 | NCT04733183 | |
| MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients | Acute Graft Versus Host Disease in Intestine; Steroid Refractory GVHD | Active, not recruiting | Phase 3 | 2024-10-17 | NCT04769895 | |
| Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | Newly Diagnosed Multiple Myeloma | Active, not recruiting | Phase 3 | 2022-09-14 | NCT03742297 |